| __timestamp | Neurocrine Biosciences, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 14400000 | 205018000 |
| Thursday, January 1, 2015 | 33800000 | 392709000 |
| Friday, January 1, 2016 | 35900000 | 299694000 |
| Sunday, January 1, 2017 | 1254000 | 397061000 |
| Monday, January 1, 2018 | 4889000 | 434100000 |
| Tuesday, January 1, 2019 | 7400000 | 782200000 |
| Wednesday, January 1, 2020 | 10100000 | 1119900000 |
| Friday, January 1, 2021 | 14300000 | 2437500000 |
| Saturday, January 1, 2022 | 23200000 | 1560400000 |
| Sunday, January 1, 2023 | 39700000 | 1815800000 |
| Monday, January 1, 2024 | 34000000 | 1970500000 |
Data in motion
In the competitive world of biotechnology, understanding cost structures is crucial. Regeneron Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc. offer a fascinating comparison. Over the past decade, Regeneron's cost of revenue has consistently dwarfed that of Neurocrine, peaking in 2021 at nearly 2.44 billion, a staggering 6,000% higher than Neurocrine's 39.7 million in 2023. This disparity highlights Regeneron's expansive operations and market reach. Neurocrine, while smaller, has shown a steady increase in its cost of revenue, growing by approximately 175% from 2014 to 2023. This growth reflects its strategic investments and scaling efforts. The data underscores the diverse strategies these companies employ to navigate the biotech landscape, with Regeneron focusing on large-scale operations and Neurocrine on targeted growth. As the industry evolves, these insights provide a window into the financial dynamics shaping biotech's future.
Regeneron Pharmaceuticals, Inc. vs Insmed Incorporated: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and HUTCHMED (China) Limited's Expenses
Cost of Revenue Comparison: Regeneron Pharmaceuticals, Inc. vs Agios Pharmaceuticals, Inc.
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
Regeneron Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Dr. Reddy's Laboratories Limited's Expenses
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Corcept Therapeutics Incorporated
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Geron Corporation
Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored